Clinical and mycological outcomes of candidaemia and/or invasive candidiasis by Candida spp. and antifungal susceptibility: pooled analyses of two randomized trials of rezafungin versus caspofungin
Rezafungin appears to be an effective treatment for candidaemia/invasive candidiasis irrespective of baseline Candida species.
Authors
- Patrick M. Honoré (ORCID: https://orcid.org/0000-0002-6697-4890)
- Jeffrey B. Locke (ORCID: https://orcid.org/0000-0001-8145-0828)
- Àlex Soriano (ORCID: https://orcid.org/0000-0002-9374-0811)
- Emmanuel Roilides (ORCID: https://orcid.org/0000-0002-0202-364X)
- Matteo Bassetti (ORCID: https://orcid.org/0000-0002-0145-9740)
- Mariana Castanheira (ORCID: https://orcid.org/0000-0003-0126-1782)
- Cecília G Carvalhaes (ORCID: https://orcid.org/0000-0002-2734-3754)
- Nick Manamley (ORCID: https://orcid.org/0009-0003-9325-0323)
- Saad Nseir (ORCID: https://orcid.org/0000-0002-7618-0357)
- Oliver A. Cornely (ORCID: https://orcid.org/0000-0001-9599-3137)
- António Ramos (ORCID: https://orcid.org/0000-0002-4840-9425)
- Maiken Cavling Arendrup (ORCID: https://orcid.org/0000-0002-4747-0144)
- Taylor Sandison
Institutions
- University of Cologne (DE)
- Centre Hospitalier Universitaire de Lille (FR)
- CHU Dinant Godinne UCL Namur (BE)
- Mundipharma (United Kingdom) (GB)
- JMI Laboratories (US)
- Cidara Therapeutics (United States) (US)
- University of Genoa (IT)
Publication Details
- Journal
- Clinical Microbiology and Infection
- Published
- 2024-11-22
- DOI
- https://doi.org/10.1016/j.cmi.2024.11.029
- Citations
- 5
- Primary Topic
- Antifungal resistance and susceptibility
- Type
- article
- Field-Weighted Citation Impact
- 1.95
Funders
- Cidara Therapeutics
- Mundipharma Research Limited